

**CORIMUNO-TOCI 1– Hermine, O; et al. *JAMA Intern Med* 2021 (Published: Oct 20, 2020)**

<b>Study Design</b>	Multicenter, open-label, bayesian, RCT – <b>Moderate/Severe COVID-19 (1:1)</b>
<b>Location</b>	France – 9 hospitals
<b>Inclusion</b>	Moderate/Severe COVID-19 pneumonia + need O <sub>2</sub> at least 3 L/min but no MV or ICU admission
<b>Exclusion</b>	HFO/NIV/MV or WHO-CPS of 6 or more (with HFO, NIV, or MV)
<b>Intervention</b>	Tocilizumab 8 mg/kg IV (up to 800 mg), followed by a second dose of 400 mg 2 days later if oxygenation did not improve
<b>Control</b>	Usual care

	<b>Tocilizumab n=63</b>	<b>Control n=67</b>
<b>Primary Outcomes</b>		
Day 4 WHO-CPS score > 5	12 (19%)	19 (28%)
At least 1 event (HFO, NIV, MV or death) at day 14	15 (24%)	24 (36%)
MV or death at day 14	17%	27%
Death at day 14	11%	9%
Death at day 28	11%	12%

**Comments:**

Prior and during corticosteroids, treatment occurred in 22% and 14% in the tocilizumab arm.

**Abbreviations:**

HFO, high-flow oxygen; ICU, intensive care unit; MV, mechanical ventilation; NIV, noninvasive ventilation; O<sub>2</sub>, oxygen; RCT, randomized controlled trial; WHO-CPS, World Health Organization 10-Point Clinical Progression Scale.